The potential of secretogranin V as a prognostic biomarker in non-small cell lung cancer

Weisong Zhang ^1,2, Rui Wang ^1,2, Rongqi Guo ^1,2

⁰Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.

Scientific Reports +

|

May 13, 2025

View abstract on PubMed

Summary

Secretogranin V (SCG5) is upregulated in non-small cell lung cancer (NSCLC) and is linked to poorer patient survival. This suggests SCG5 is a potential prognostic biomarker for NSCLC, aiding in predicting patient outcomes.

Area Of Science

Oncology
Biomarker Discovery
Molecular Pathology

Background

Secretogranin V (SCG5) shows aberrant expression in various cancers, potentially influencing tumor progression and prognosis.
Non-small cell lung cancer (NSCLC) requires novel prognostic biomarkers to improve patient management.
Understanding the role of SCG5 in NSCLC is crucial for developing targeted diagnostic and therapeutic strategies.

Purpose Of The Study

To investigate the potential of Secretogranin V (SCG5) as a prognostic biomarker in non-small cell lung cancer (NSCLC).
To analyze SCG5 expression patterns and their correlation with patient survival and immune infiltration in NSCLC.

Main Methods

Bioinformatics analysis of TCGA and GEO pan-cancer datasets.
Western blotting and immunofluorescence assays on NSCLC tissues and cell lines.
Kaplan-Meier survival analysis and COX regression modeling.

Main Results

SCG5 was consistently upregulated across multiple cancer types and significantly higher in NSCLC tumor tissues versus normal tissues (p < 0.001).
Elevated SCG5 expression correlated with lower overall survival rates in NSCLC patients.
SCG5 was identified as an independent prognostic factor for NSCLC and showed correlations with immune cell infiltration.

Conclusions

Secretogranin V (SCG5) demonstrates significant potential as a valuable prognostic biomarker for non-small cell lung cancer (NSCLC).
SCG5's association with prognosis and immune infiltration warrants further investigation for diagnostic and therapeutic applications in NSCLC.

Keywords:

Bioinformatics analysis Biomarker Non-small cell lung Cancer Prognosis SCG5